SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS Interest Income
Income earned on cash, deposits, and investments held by the company.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Interest Income · Q3 FY2026 · quarter ended Sep 2026
Interest income growth accelerates
Q3 FY2026 interest income of $1.22M rose 317.1% year over year, ahead of the +270.3% change in trailing-twelve-month interest income. Sequentially, it rose 18.9% from the prior quarter. Over 3 fiscal years it compounded at +64.5% a year.
Context
- Interest income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +317.1% holds above the trailing-twelve-month pace of +270.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 1.41M USD
- Year-over-year change
- +123.3%
- 4-year CAGR
- +291.6%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.41M | +123.3% |
| FY2024 | 2024-12-31 | 632K | +20.4% |
| FY2023 | 2023-12-31 | 525K | +65.6% |
| FY2022 | 2022-12-31 | 317K | +5183.3% |
| FY2021 | 2021-12-31 | 6K | — |
Interest Income vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +270.3% is the 2nd highest of 10, against a peer median of -10.2%.
- Over three fiscal years its annual growth of +64.5% compares with a peer median of +84.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $129.34M USD | +86.7% | — | 2.2% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥79.89M CNY | +111.1% | +101.8% | 14.3% |
| LTM Mar 2026 | $43.41M USD | -18.5% | +128.0% | 19.3% | |
| LTM Aug 2026 | $18.56M USD | -20.1% | +84.3% | 2.6% | |
| LTM Sep 2026 | $18.04M USD | +57.2% | +1228.3% | — | |
| LTM Mar 2026 | $11.63M USD | -10.2% | — | — | |
| LTM Mar 2026 | $10.16M USD | -24.2% | +42.5% | 29.2% | |
| LTM Mar 2026 | $5.93M USD | -29.4% | +26.0% | 3.8% | |
| LTM Mar 2026 | $4.13M USD | +409.6% | +59.1% | 34.8% | |
| LTM Sep 2026 | $3.68M USD | +270.3% | +64.5% | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding SLS) | — | -10.2% | +84.3% | 9.0% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.6M | 1M | 0 | 0 | 0 |
| Cost of Revenue | 200K | 100K | 0 | 0 | 0 |
| Gross Profit | 7.4M | 900K | 0 | 0 | 0 |
| Gross Margin | 97.4% | 90.0% | — | — | — |
| Research & Development | 21.37M | 30.27M | 24.01M | 19.1M | 16.02M |
| Selling, General & Admin | 11.32M | 12.58M | 13.86M | 12.42M | 12.25M |
| Operating Expenses | 32.69M | 42.85M | 37.87M | 31.51M | 28.27M |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| EBITDA | (18.32M) | (31.49M) | 529K | 632K | (26.86M) |
| EBITDA Margin | -241.1% | -3149.3% | — | — | — |
| Operating Income | (25.29M) | (41.95M) | (37.87M) | (31.51M) | (28.27M) |
| Operating Margin | -332.8% | -4195.0% | — | — | — |
| Interest Income | 6K | 317K | 525K | 632K | 1.41M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.36M | 649K | 529K | 632K | 1.41M |
| Income Before Tax | (20.94M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Pre-Tax Margin | -275.5% | -4130.1% | — | — | — |
| Income Tax Expense | (237K) | 0 | 0 | 0 | 0 |
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Net Margin | -272.4% | -4130.1% | — | — | — |
| EPS (Basic) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| EPS (Diluted) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| Weighted Avg Shares | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
| Weighted Avg Shares (Diluted) | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.